Psoriasis is a chronic inflammatory skin disease characterized by the hyperproliferation and aberrant differentiation of epidermal keratinocytes. It is a debilitating condition that can cause significant physical and emotional distress. Natural anti-psoriatic agents have been investigated as alternatives to conventional allopathic medications, as they have notable limitations and drawbacks. Curcumin and tea tree oil are cost-efficient and effective anti-inflammatory medicines with less adverse effects compared to synthetic psoriasis medications. Our research endeavors to harness the therapeutic potential of these natural compounds by developing an herbal anti-psoriatic topical drug delivery system. This novel method uses curcumin and tea tree oil to create a bi-phasic emulgel drug delivery system. Formulations F1 (gel) and F2 (emulgel) have high drug content percentages of 84.2% and 96.7%, respectively. The emulgel showed better spreadability for cutaneous applications, with a viscosity of 92,200 ± 943 cp compared to the gel’s 56,200 ± 1725 cp. The emulgel released 94.48% of the drugs, compared to 87.58% for the gel. These formulations conform to the zero-order and Higuchi models, and their stability over a three-month period is crucial. In vivo, the emulgel healed psoriasis symptoms faster than the usual gel. The gathered results confirmed the emulgel’s potential as a drug delivery method, emphasizing the complementary benefits of tea tree oil and curcumin as an effective new therapy for psoriasis.

Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are chronic inflammatory illnesses categorized by joint pain and swelling, along with systemic symptoms. The distinction between RA and PsA may be difficult to determine since their clinical presentations and symptoms are so similar. RA and PsA are treated in a palliative manner since they are not curable diseases. Allopathic medicines have serious side effects, and long term-consumption decreases patient quality of life. Hyperacidity, edema, stomach ulcers, gastrointestinal bleeding, perforation, and reduced appetite are some of the most common adverse effects. Curcumin, the primary active component within Curcuma longa (turmeric), has been demonstrated to be helpful in treating RA and PsA, with effectiveness attributed to its mode of activity. This chapter defines the correlation between RA and PsA and reports on the use and mechanism of curcumin in the management of these conditions. According to various literature surveys and evidence, it can be concluded that curcumin is a safe and effective therapeutic option for managing RA and PsA compared to synthetic medications.

Introduction: Polycystic Ovary Syndrome (PCOS) presents itself as a hormonal and metabolic disorder that affects women during their reproductive years through three primary symptoms. The existing treatments encounter two main obstacles, which include their limited bioavailability and their tendency to produce adverse effects throughout the body. The application of nanotechnology to drug delivery via nanocarriers and nanoformulations offers a solution to existing challenges in the field. Methods: The research team conducted a complete literature review, which examined scientific databases from 1 May 2020 until 1 May 2025. The research team used specific keywords, along with Boolean operators (AND, OR, NOT), to locate relevant peer-reviewed articles, clinical studies, and patents focused on nanocarrier-based nanoformulations for PCOS. Results: The study results demonstrate that nanoformulations that use nanocarrier technology improve PCOS treatment through better drug solubility and bioavailability and precise medication delivery. The combination of multiple medications into one formulation leads to better treatment results while decreasing adverse reactions. The rise in patent applications demonstrates that personalized nanomedicine and hybrid delivery systems are becoming increasingly innovative as they develop. Discussion: A Nanocarrier-based PCOS treatment system provides two advantages through its ability to increase drug solubility and bioavailability while delivering targeted therapies that produce fewer adverse events. Hormonal and metabolic imbalances in patients are effectively treated by multidrug nanoformulations, which achieve better outcomes through their simultaneous multiple actions. The patent system shows that personalized medicine and hybrid nanomedicine approaches have become increasingly innovative. The results from preclinical studies show potential benefits, yet there remain obstacles, including difficulties in scaling operations, determining product safety, and proving linkages between two different fields Conclusion: The development of advanced nanocarriers represents a new medical treatment approach that enables precise medication delivery and better treatment results for patients with PCOS. The increasing volume of clinical research, together with the growing number of patents, indicates high commercial potential, yet additional research on safety and practical applications is required.